Medium materiality6/10
Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
Why it may matterVerify against the original reporting
bearish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Wolfe Research downgraded NTLA to Underperform; target cut to $9 from $13.04.
- NTLA downgraded to Underperform by Wolfe Research; target $9 (from $13.04).
Key facts
- 01
Target: $9
- 02
Posted price: $13.04
- 03
Analyst firm: Wolfe Research
- 04
Analyst: Andy Chen
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.